Overview A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021 Status: Completed Trial end date: 2008-03-01 Target enrollment: Participant gender: Summary This is a multi-center study to evaluate hormone levels with the oral contraceptive regimen DR-1021. Phase: Phase 3 Details Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.Teva Branded Pharmaceutical Products, R&D Inc.Treatments: DesogestrelEstradiolEstradiol 17 beta-cypionateEstradiol 3-benzoateEstradiol valerateEthinyl EstradiolHormonesOviolPolyestradiol phosphate